Completed OBSERVATIONAL NCT05450874

A Novel MSE Score to Predict rHCC Patients

A Novel MSE Score to Predict the Postoperative Prognosis of Patients With Ruptured Hepatocellular Carcinoma

Sponsor: Tongji Hospital

Conditions HCC

Interventions hepatectomy

Updated 3 times since 2022 Last updated: Jul 8, 2022 Started: Feb 1, 2010 Primary completion: Mar 1, 2017 Completion: Jun 1, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates HCC and is currently completed. Tongji Hospital leads this study, which shows 3 recorded versions since 2010 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

3 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Sep 2022 — Jul 2024 [monthly]

Completed

First recorded

Feb 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Tongji Hospital

Data source: Tongji Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.